Oxatomide in seasonal rhinoconjunctivitis.
The new antiallergic drug oxatomide was evaluated in 40 schoolchildren suffering from severe allergic seasonal rhinoconjunctivitis. Antihistamine drugs had earlier given insufficient symptomatic relief. Double-blind technique was used. There was no significant difference in effect between oxatomide, the antihistamine cinnarizine in combination with phenylpropanolamine and placebo. The results do not support the hypothesis that oxatomide is superior to antihistamine drugs in the treatment of severe seasonal rhinoconjunctivitis.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002936:Cinnarizine / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003231:Conjunctivitis / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy; D008297:Male; D010665:Phenylpropanolamine / Q000009:adverse effects / Q000627:therapeutic use; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D010919:Placebos; D006109:Poaceae; D011058:Pollen; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D014197:Trees
D010879:Piperazines; D010919:Placebos; D010665:Phenylpropanolamine; D002936:Cinnarizine; C015408:oxatomide